Immunotherapy will rule at ESMO

This weekend, the largest European cancer meeting will kick off — remotely, of course. We’ve got our eyes on a fair few studies that'll be presented at ESMO, and it looks as though the immuno-oncology space will offer some of the most intriguing bits. For instance, John B. Haanen, ESMO’s scientific chair, told Medscape that a duo of lung cancer presentations will offer some “exciting new [results] that I am sure will change clinical practice.”

Another highly anticipated unveiling: follow-up data from the CheckMate trials for advanced renal cell carcinoma. Not only will we get updated on the efficacy of combination immunotherapies for this disease, but we’ll learn more about quality of life.

Notably, and also per MedScape, conference organizers are holding out hope that next year’s ESMO will be held — in person! — in Paris.

You can sign up for our flash ESMO newsletter here to get deeper insights on the data that’ll be presented from Saturday to Monday.